NextCure, Inc. - NXTC STOCK NEWS

NextCure, Inc. (NXTC) announced it will present new data from two studies at the 63rd American Society of Hematology annual meeting from December 11-14, 2021. The studies focus on the role of Siglec-15 in childhood leukemia and the effects of LAIR-1 monoclonal antibodies in acute myeloid leukemia, in collaboration with Emory and Vanderbilt Universities. These findings aim to advance the understanding and treatment of these cancers, specifically for patients not adequately addressed by existing therapies.

NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will hold a Virtual Oncology Pipeline Update Event on November 15, 2021, at 4:30 p.m. ET. The event aims to provide insights into its oncology pipeline, including data from the Society for Immunotherapy of Cancer’s 36th Annual Meeting. Dr. Roy Herbst will address unmet needs in lung cancer treatment. Participants can join via conference call or webcast, with a replay available for 30 days after the event.

NextCure, Inc. (Nasdaq: NXTC) appointed Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB) while Ethan Shevach, M.D., retires. These new members bring extensive experience in oncology and immunology, crucial for advancing NextCure's clinical programs. Dr. Jaffee focuses on immune-based therapies, Dr. Matulonis on targeted therapies for gynecologic cancers, and Dr. Zou on cancer immunology. NextCure aims to enhance its capabilities in developing first-in-class immunomedicines.

NextCure, a clinical-stage biopharmaceutical company, announced the publication of preclinical data in Frontiers in Immunology regarding NC410, a first-in-class immunomedicine. The study indicates that collagen fragments in cancer can suppress T cell activity via LAIR-1, but this effect can be reversed by LAIR-2 and NC410. Currently in a Phase 1/2 clinical trial for advanced solid tumors, NC410 aims to provide a new therapeutic option for patients resistant to existing immunotherapies. Initial clinical data will be shared at a conference in November.

NextCure, Inc. (Nasdaq: NXTC) announced the appointment of Dr. Ellen G. Feigal and Dr. Anne Borgman to its Board of Directors, bringing extensive experience in clinical and biopharmaceutical sectors. This change follows the resignation of Dr. Stella Xu. Dr. Feigal specializes in biologics and oncology, while Dr. Borgman has leadership experience in hematology and oncology drug development. Both appointments aim to support NextCure's ongoing clinical programs and the advancement of new immunomedicines for cancer treatment.

NextCure (Nasdaq: NXTC) announced new data presentation from clinical studies on NC318 and NC410 at the Society for Immunotherapy of Cancer meeting from November 10-14, 2021. NC318 targets Siglec-15 to treat advanced solid tumors, while NC410 is focused on blocking LAIR-1 to enhance immune response. Oral presentations will highlight NC318’s clinical benefits, with poster sessions discussing NC410’s safety, tolerability, and immune modulation. Both drugs aim to address unmet needs in cancer therapy, showcasing NextCure's potential in developing innovative immunomedicines.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical firm, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th. The presentation will be pre-recorded and available via an audio webcast on the company’s website, with replays accessible for 30 days post-event. NextCure is focused on developing novel immunomedicines aimed at treating cancer and immune-related diseases, particularly for patients not responding to current therapies. Their proprietary FIND-IO™ platform facilitates research into immune cell targets.

NextCure, a clinical-stage biopharmaceutical company focused on developing novel immunomedicines for cancer, announced its participation in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 PM ET. Investors can access a live audio webcast on NextCure's website, with a replay available for 30 days post-event. The company uses its FIND-IO™ platform to discover immune cell targets, aiming to provide new therapies for patients unresponsive to current treatments.

NextCure, Inc. (Nasdaq: NXTC) reported its Q2 2021 financial results, showcasing progress in clinical trials, including the NC318 Phase 2 monotherapy trial. Key updates include resumed enrollment in NSCLC adenocarcinoma and a revised dosing regimen aimed at enhancing drug exposure. Financially, cash and equivalents decreased to $249.5 million, while net loss rose to $18.0 million due to increased operational costs. The company anticipates data updates from ongoing trials and expects its funds to last through the second half of 2023.